Currently, epidermal growth factor receptor (EGFR) is a crucial molecule for targeted therapy (Naylor et al., 2016); EGFR tyrosine kinase inhibitors (EGFR-TKIs) have been extensively adopted in EGFR-mutated NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.